Cystic fibrosis heterozygotes do not have increased platelet activation

Thromb Res. 2007;121(2):159-62. doi: 10.1016/j.thromres.2007.04.004. Epub 2007 May 29.


Introduction: We have previously demonstrated platelet hyperreactivity in cystic fibrosis (CF) patients. Carriers of one CF mutation (heterozygotes) have been shown to have abnormalities related to the presence of only one-half the normal amount of CF transmembrane conductance regulator protein. Platelet hyperreactivity in CF heterozygotes would be an important cardiovascular risk factor, since approximately 1 in 25 Caucasians is a CF carrier.

Materials and methods: We used highly sensitive assays of platelet activation to assess the difference between 16 CF heterozygotes and 16 age- and sex-matched healthy controls without CF mutations.

Results: We found no difference in platelet activation between CF heterozygotes and controls.

Conclusions: The 50% reduction in the CF transmembrane conductance regulator protein in heterozygotes is insufficient to cause platelet activation.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Case-Control Studies
  • Cystic Fibrosis / genetics*
  • Cystic Fibrosis / physiopathology*
  • Cystic Fibrosis Transmembrane Conductance Regulator / genetics*
  • Female
  • Heterozygote*
  • Humans
  • Male
  • Middle Aged
  • Platelet Activation / genetics*


  • Cystic Fibrosis Transmembrane Conductance Regulator